Suppr超能文献

改良的肿瘤-淋巴结-转移分期系统结合淋巴管侵犯在食管鳞状细胞癌患者中的分期表现。

The staging performance of a modified tumor-node-metastasis staging system incorporated with lymphovascular invasion in patients with esophageal squamous cell carcinoma.

作者信息

Zhuang Weitao, Wu Hansheng, Chen Rixin, Ben Xiaosong, Huang Shujie, Zhou Zihao, Wu Junhan, Tang Yong, Qiao Guibin

机构信息

Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.

Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.

出版信息

Front Oncol. 2022 Oct 13;12:1018827. doi: 10.3389/fonc.2022.1018827. eCollection 2022.

Abstract

BACKGROUND

Lymphovascular invasion (LVI) is recognized as an unfavorable prognostic factor for many solid tumors. However, its staging value has not been adequately illustrated in esophageal squamous cell carcinoma (ESCC).

METHODS

The clinicopathologic relevance and prognostic impact of LVI were retrospectively analyzed in 822 patients with surgically treated ESCC. Univariate and multivariate analyses were used to determine the independent prognostic factors. Subgroup analyses stratified by pathological stages, nodal status and invasive depth were conducted using Kaplan-Meier method and log-rank test. Multiple staging models based on overall survival (OS) were constructed using Cox regression and evaluated by Harrell's concordance index (C-index), integrated discrimination improvement (IDI), and net reclassification index (NRI).

RESULTS

LVI was detected in 24.6% of ESCC patients, and its prevalence increased with a higher pathological stage (p < 0.001). In multivariate analysis, LVI was found to be an independent prognostic factor for OS [Hazard ratio (HR) = 1.545, 95% CI, 1.201-1.986), and was associated with unfavorable outcomes in stage I to III ESCC, regardless of nodal status and invasive depth. The staging model that incorporated LVI as an independent factor achieved the greatest improvement in accuracy (ΔC-index: 2.9%), and the greatest added value (IDI 2.8%, p < 0.01; NRI 13.7%, p < 0.05) for prediction of OS in ESCC patients.

CONCLUSIONS

LVI can facilitate further survival stratification in ESCC patients. The adoption of LVI as an independent staging factor in the current cancer staging system should be considered and further validated.

摘要

背景

淋巴管侵犯(LVI)被认为是许多实体瘤的不良预后因素。然而,其在食管鳞状细胞癌(ESCC)中的分期价值尚未得到充分阐明。

方法

回顾性分析822例接受手术治疗的ESCC患者中LVI的临床病理相关性及预后影响。采用单因素和多因素分析确定独立预后因素。使用Kaplan-Meier法和对数秩检验对病理分期、淋巴结状态和浸润深度进行分层的亚组分析。基于总生存期(OS)构建多个分期模型,采用Cox回归分析,并通过Harrell一致性指数(C指数)、综合判别改善(IDI)和净重新分类指数(NRI)进行评估。

结果

24.6%的ESCC患者检测到LVI,其发生率随病理分期升高而增加(p<0.001)。多因素分析中,LVI被发现是OS的独立预后因素[风险比(HR)=1.545,95%置信区间,1.201-1.986],并且在Ⅰ至Ⅲ期ESCC中,无论淋巴结状态和浸润深度如何,LVI均与不良预后相关。将LVI作为独立因素纳入的分期模型在预测ESCC患者OS时,准确性提高最大(ΔC指数:2.9%),且附加值最大(IDI 2.8%,p<0.01;NRI 13.7%,p<0.05)。

结论

LVI有助于进一步对ESCC患者进行生存分层。应考虑将LVI作为当前癌症分期系统中的独立分期因素并进一步验证。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验